Content about Olanzapine

January 29, 2013

Eli Lilly reports 1% Q4 decline from Zyprexa patent expiration

Eli Lilly and Company reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

June 18, 2012

Greenstone launches generic Zyprexa

Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

April 25, 2012

Sun launches generic version of Zyprexa

Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.

April 24, 2012

Dr. Reddy's launches generic version of Zyprexa

Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

April 24, 2012

Mylan launches generic schizophrenia, bipolar disorder drug

Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

February 3, 2012

Teva launches generic schizophrenia, bipolar disorder drug

Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

October 27, 2011

Innopharma receives FDA approval for generic Zyprexa injection

A company focused on developing niche generic and specialty pharmaceutical products has received regulatory approval from the Food and Drug Administration for its version of a psychiatric drug.

October 25, 2011

Sales, profits increase for Dr. Reddy's in Q2

Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

October 24, 2011

FDA approves generic versions of Zyprexa

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

October 20, 2011

Prasco to market authorized generic Zyprexa

Prasco Labs will make authorized generic versions of two psychiatric drugs made by Eli Lilly under a partnership between the two companies announced Thursday.

February 18, 2011

As innovaters prep for patent cliff, generics prosper from patent losses

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol- lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health. 

November 14, 2010

Patent cliff to bring short-term boon to generic industry

Look for a big surge in brand-to-generic drug switches at the pharmacy counter over the...

October 6, 2010

IMS Health projects growth for Rx market

The global pharmaceutical market will reach a value of $880 billion next year, according to...

July 6, 2010

CVS Caremark study: Less-restrictive generic laws could curb state Medicaid costs

Changing generic substitution laws in favor of less-restrictive regulations could save states struggling to pay...

March 17, 2010

Lilly comments on drug theft at Connecticut facility

Drugs stolen from an Eli Lilly warehouse in Connecticut Sunday unlikely are to make it...